Aethlon Medical, Inc. said on Monday that its study conducted on Hepatitis C-infected individuals in India who received Hemopurifier therapy showed promise and the company is now set to start its first human clinical studies in the U.S.
Rapid virologic response (RVR) and sustained virologic response (SVR) rates were positive in the study led by Dr. Vijay Kher at the Medanta Medicity.
The Aethlon Hemopurifier is a bio-filtration device that rapidly eliminates viruses and immunosuppressive proteins from the circulatory system of infected people.
In addition to disclosing the RVR and SVR rates, Aethlon also said the Hemopurifier study proved it could be administered safely in non-dialysis patients who were infected with Hepatitis C, could be combined with an already-established drug regimen and established a protocol where researchers were able to accurately count the number of viruses captured by the Hemopurifier. Researchers were able to capture as many as 300 billion copies of the Hepatitis C virus during one six-hour treatment.
In the study, Hepatitis C-infected individuals received three six-hour Hemopurifier treatments during the first three days of a 48-week peginterferon+ribavirin treatment regimen. Aethlon said that Hemopurifier therapy was well tolerated and had no adverse events in 12 patients.
Ten of the 12 patients achieved a sustained virologic response and seven of the 12 patients achieved a rapid virologic rate.